Last reviewed · How we verify
Biosynthetic Human Insulin Injection
At a glance
| Generic name | Biosynthetic Human Insulin Injection |
|---|---|
| Also known as | Brand Name: Novolin 30R |
| Sponsor | Servier (Tianjin) Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
- Brain Insulin Resistance in Mood Disorders (PHASE1, PHASE2)
- Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia (PHASE4)
- Endotherapy for Painless Chronic Pancreatitis (NA)
- Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents (PHASE1, PHASE2)
- Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I (EARLY_PHASE1)
- Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes (PHASE4)
- Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: